<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703699</url>
  </required_header>
  <id_info>
    <org_study_id>MLS/MYV-3/European study</org_study_id>
    <nct_id>NCT04703699</nct_id>
  </id_info>
  <brief_title>Myval European Study of Myval™ THV System Implanted in Patients With Native Severe Aortic Valve Stenosis.</brief_title>
  <official_title>Myval European Study: A Retrospective, Multicentre, Observational Study in Patients Presenting With Native Severe Aortic Valve Stenosis and Treated With Myval™ Transcatheter Heart Valve System in Real-world Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meril Life Sciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meril Life Sciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myval European Study: A retrospective, multicentre, observational study in patients&#xD;
      presenting with native severe aortic valve stenosis and treated with Myval™ Transcatheter&#xD;
      Heart Valve System in real-world setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myval European Study: A retrospective, multicentre, observational study in patients&#xD;
      presenting with native severe aortic valve stenosis and treated with Myval™ Transcatheter&#xD;
      Heart Valve System in real-world setting.&#xD;
&#xD;
      This study shall retrospectively collect the data of minimum 200 consecutive patients treated&#xD;
      with Myval THV system between 01-June-2019 to 30-June-2020 from approximately 15&#xD;
      participating sites in Europe.&#xD;
&#xD;
      Primary Endpoint:&#xD;
&#xD;
      Primary Combined Safety and Effectiveness Endpoint: [Time frame: 30 days]&#xD;
&#xD;
      It is the composite of following:&#xD;
&#xD;
        -  All-cause mortality&#xD;
&#xD;
        -  All stroke (disabling and non-disabling)&#xD;
&#xD;
        -  Life-threatening or disabling bleeding&#xD;
&#xD;
        -  Acute kidney injury (stage 2 or 3)&#xD;
&#xD;
        -  Major vascular complications&#xD;
&#xD;
        -  Moderate or severe prosthetic valve regurgitation&#xD;
&#xD;
        -  Conduction system disturbances resulting in a new permanent pacemaker implantation.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        1. All-cause mortality (VARC-2 defined criteria) [Time Frame: Through 30 days]&#xD;
&#xD;
        2. All stroke (disabling and non-disabling) [Time Frame: Through 30 days]&#xD;
&#xD;
             -  Disabling stroke: an mRS score of 2 or more at 90 days and an increase in at least&#xD;
                one mRS category from an individual's pre-stroke baseline&#xD;
&#xD;
             -  Non-disabling stroke: an mRS score of 2 at 90 days or one that does not result in&#xD;
                an increase in at least one mRS category from an individual's pre-stroke baseline&#xD;
&#xD;
           Note: As per VARC-2, the assessment of the mRS should be done at all scheduled visits in&#xD;
           a trial and at 90 days after the onset of any stroke.&#xD;
&#xD;
        3. Acute Kidney Injury (AKI) based on the Acute Kidney Injury Network (AKIN) System Stage 3&#xD;
           (including renal replacement therapy) or Stage 2 [Time Frame: Through 30 days]&#xD;
&#xD;
        4. Life-threatening or disabling bleeding (VARC-2 criteria) [Time Frame: Through 30 days]&#xD;
&#xD;
        5. Moderate or severe prosthetic valve regurgitation [Time Frame: Through 30 days]&#xD;
&#xD;
        6. New permanent pacemaker implantation [Time Frame: Through 30 days] New permanent&#xD;
           pacemaker implantation rates will be analyzed further based on the patient's history of&#xD;
           left and/or right bundle branch block.&#xD;
&#xD;
        7. Conduction disturbances and arrhythmias according to VARC-2 [Time Frame: Through 30&#xD;
           days]&#xD;
&#xD;
        8. Device success (VARC-2 criteria) [Time Frame: Pre-discharge]&#xD;
&#xD;
        9. Early safety at 30 days (VARC-2 criteria) [Time Frame: After 30 days of index procedure]&#xD;
&#xD;
       10. Clinical efficacy after 30 days (VARC-2 criteria) [Time Frame: After 30 days of index&#xD;
           procedure]&#xD;
&#xD;
       11. Time-related valve safety (VARC-2 criteria) [Time Frame: Through 30 days]&#xD;
&#xD;
       12. Vascular and access related complications (VARC-2 criteria) [Time Frame: Pre-discharge,&#xD;
           Through 30 days]&#xD;
&#xD;
       13. Major vascular complications (VARC-2 criteria) [Time Frame: Pre-discharge, Through 30&#xD;
           days]&#xD;
&#xD;
       14. Functional improvement from baseline as measured per&#xD;
&#xD;
           a. NYHA functional classification [Time frame: Baseline, 30 days]&#xD;
&#xD;
       15. Echocardiographic End Points&#xD;
&#xD;
             -  Effective orifice area (EOA)&#xD;
&#xD;
             -  Index effective orifice area (iEOA)&#xD;
&#xD;
             -  Mean aortic valve gradient&#xD;
&#xD;
             -  Peak aortic valve gradient&#xD;
&#xD;
             -  Peak aortic velocity&#xD;
&#xD;
             -  Transvalvular, paravalvular and total aortic regurgitation&#xD;
&#xD;
             -  Left ventricular ejection fraction (LVEF)&#xD;
&#xD;
             -  Valve calcification&#xD;
&#xD;
             -  Cardiac output and cardiac index [Time frame: Through 30 days]&#xD;
&#xD;
       16. Patient-prosthesis Mismatch: [Time Frame: Post-procedure, predishcarge, Through 30 days]&#xD;
           Severity patient-prosthesis-mismatch will be based on following&#xD;
&#xD;
             -  For subjects with BMI &lt; 30 kg/m2, index effective orifice area (EOAi) 0.85 - 0.65&#xD;
                cm2 /m2 for moderate and &lt;0.65 cm2 /m2 for severe&#xD;
&#xD;
             -  For subjects with BMI ≥30 kg/m2, index effective orifice area (EOAi) 0.90 - 0.60&#xD;
                cm2 /m2 for moderate and &lt;0.60 cm2 /m2 for severe BMI = weight(kg)/(height (m)) 2&#xD;
&#xD;
       17. Length of index hospital stay. [Time frame: At discharge]&#xD;
&#xD;
           - Number of days from hospital admission to discharge.&#xD;
&#xD;
       18. Hospitalization for valve-related symptoms or worsening congestive heart failure (New&#xD;
           York Heart Association [NYHA] class III or IV) [Time Frame: Through 30 days]&#xD;
&#xD;
       19. New onset of atrial fibrillation or atrial flutter [Time Frame: Post-procedure,&#xD;
           Pre-discharge and 30 days]&#xD;
&#xD;
       20. Endocarditis [Time Frame: Through 30 days]&#xD;
&#xD;
       21. Major bleeding event [Time Frame: Through 30 days]&#xD;
&#xD;
       22. Other Endpoints:&#xD;
&#xD;
             -  Myocardial rupture [Time Frame: During procedure]&#xD;
&#xD;
             -  Paravalvular leak [Time Frame:Through 30 days]&#xD;
&#xD;
             -  Degree of over- or under-expansion of Myval [Time Frame: During procedure]&#xD;
&#xD;
             -  Accuracy of deployment in relation to the annular plane [Time Frame: During&#xD;
                procedure]&#xD;
&#xD;
             -  Pacemaker deployment (and the symptoms resulting in it) [Time Frame: Through 30&#xD;
                days]&#xD;
&#xD;
             -  Interference with the mitral valve; and [Time Frame: During procedure]&#xD;
&#xD;
             -  Interference with the LVOT [Time Frame: During procedure]&#xD;
&#xD;
                  -  If the endpoint data is available through 1 year, it will also be collected&#xD;
                     and analyzed.&#xD;
&#xD;
      Clinical efficacy data will be collected only for patients with availability of data after 30&#xD;
      days follow-up.&#xD;
&#xD;
      Long term clinical follow up by telephonic interview will be conducted for all patients who&#xD;
      have completed 30 days safety follow-up, at 1 year, 3 year and 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Effectiveness as defined by the Valve Academic Research Consortium-2 (VARC-2)</measure>
    <time_frame>30 day</time_frame>
    <description>It is the composite of following&#xD;
All-cause mortality&#xD;
All stroke (disabling and non-disabling)&#xD;
Life-threatening or disabling bleeding&#xD;
Acute kidney injury (stage 2 or 3)&#xD;
Major vascular complications&#xD;
Moderate or severe prosthetic valve regurgitation&#xD;
Conduction system disturbances resulting in a new permanent pacemaker implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 day</time_frame>
    <description>Number of mortality as per VARC - 2 Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All stroke (disabling and non-disabling)</measure>
    <time_frame>Through 30 days</time_frame>
    <description>Number of participants as per following criteria. Disabling stroke: an mRS score of 2 or more at 90 days and an increase in at least one mRS category from an individual's pre-stroke baseline Non-disabling stroke: an mRS score of 2 at 90 days or one that does not result in an increase in at least one mRS category from an individual's pre-stroke baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury (AKI) based on the Acute Kidney Injury Network (AKIN) System Stage 3 (including renal replacement therapy) or Stage 2</measure>
    <time_frame>Through 30 days</time_frame>
    <description>Number of participants of AKI as per AKIN Network</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life-threatening or disabling bleeding</measure>
    <time_frame>Through 30 days</time_frame>
    <description>Number of participants for Life-threatening or disabling bleeding as per VARC-2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate or severe prosthetic valve regurgitation</measure>
    <time_frame>Through 30 days</time_frame>
    <description>VARC -2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New permanent pacemaker implantation</measure>
    <time_frame>Through 30 days</time_frame>
    <description>Number of participants for New permanent pacemaker implantation rates will be analyzed further based on the patient's history of left and/or right bundle branch block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conduction disturbances and arrhythmias</measure>
    <time_frame>Through 30 days</time_frame>
    <description>Number of participants for Conduction disturbances and arrhythmias as per VARC-2 Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>During hospital stay or maximum of 7 days after index procedure, whichever is earlier.</time_frame>
    <description>Number of participants for Device success as per VARC-2 Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early safety at 30 days</measure>
    <time_frame>After 30 days of index procedure</time_frame>
    <description>Number of participants for Early safety as per VARC-2 Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy after 30 days</measure>
    <time_frame>After 30 days of index procedure</time_frame>
    <description>Number of participants for Clinical efficacy as per VARC-2 Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time related valve safety</measure>
    <time_frame>Through 30 days</time_frame>
    <description>Number of participants for Time related valve safety as per VARC-2 Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular and access related complications</measure>
    <time_frame>Immediately after procedure, at 1 Month</time_frame>
    <description>Number of participants for Vascular and access related complications as per VARC-2 Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major vascular complications</measure>
    <time_frame>Immediately after procedure, at 1 Month</time_frame>
    <description>Number of participants for Major vascular complications as per VARC-2 Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional improvement from baseline as measured</measure>
    <time_frame>Baseline, 30 days</time_frame>
    <description>Number of participants for Functional improvement as per NYHA functional classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability Echocardiographic End Points</measure>
    <time_frame>At 1 Month</time_frame>
    <description>Outcome measures will be:&#xD;
Effective orifice area (EOA)&#xD;
Index effective orifice area (iEOA)&#xD;
Mean aortic valve gradient&#xD;
Peak aortic valve gradient&#xD;
Peak aortic velocity&#xD;
Transvalvular, paravalvular and total aortic regurgitation&#xD;
Left ventricular ejection fraction (LVEF)&#xD;
Valve calcification&#xD;
Cardiac output and cardiac index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-prosthesis Mismatch</measure>
    <time_frame>At 1 Month</time_frame>
    <description>Number of participants for Patient-prosthesis Mismatch as per VARC 2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of index hospital stay</measure>
    <time_frame>At 1 Month</time_frame>
    <description>Number of days from hospital admission to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for valve-related symptoms or worsening congestive heart failure (New York Heart Association [NYHA] class III or IV)</measure>
    <time_frame>Through 30 days</time_frame>
    <description>As per NYHA criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset of atrial fibrillation or atrial flutter</measure>
    <time_frame>At 1 Month</time_frame>
    <description>VARC-2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocarditis</measure>
    <time_frame>Through 30 days</time_frame>
    <description>Number of participantsfor Endocarditis as per VARC-2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding event</measure>
    <time_frame>Through 30 days</time_frame>
    <description>Number of participants for Major bleeding event as per VARC-2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial rupture</measure>
    <time_frame>During procedure</time_frame>
    <description>Number of participants for Myocardial rupture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paravalvular Leak</measure>
    <time_frame>Through 30 days</time_frame>
    <description>Number of participants for Paravalvular Leak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of over - or Under-expansion of Myval</measure>
    <time_frame>During Procedure</time_frame>
    <description>Number of participants for Degree of over - or Under-expansion of Myval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of deployment in relation to the annular plane</measure>
    <time_frame>During procedure</time_frame>
    <description>Number of participants for Accuracy of deployment in relation to the annular plane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacemaker deployment (and the symptoms resulting in it)</measure>
    <time_frame>Through 30 days</time_frame>
    <description>Number of participants for Pacemaker deployment (and the symptoms resulting in it)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interference with the mitral valve</measure>
    <time_frame>During procedure</time_frame>
    <description>Number of participants for Interference with the mitral valve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interference with the LVOT</measure>
    <time_frame>During procedure</time_frame>
    <description>Number of participants for Interference with the LVOT</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Myval Transcatheter Heart Valve System</intervention_name>
    <description>Myval™ THV is a newer-generation balloon-expandable THV characterized by a nickel-cobalt alloy frame composed of a single element - hexagon arranged in a hybrid honeycomb fashion.</description>
    <other_name>Myval THV</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who have been treated with Myval THV series will be selected for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients of this study must have received Myval THV system for treatment of native&#xD;
             severe aortic stenosis and meet all eligibility and treatment criteria as defined by&#xD;
             Hospital Heart Team and or Treating TAVR operator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashok Thakkar, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Head - Clinical Research and Medical Writing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashok Thakkar, Ph.D.</last_name>
    <phone>+91-260-3063880</phone>
    <phone_ext>242</phone_ext>
    <email>Ashok.Thakkar@merillife.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amphia Ziekenhui</name>
      <address>
        <city>Breda</city>
        <state>North Brabant</state>
        <zip>4818</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Cliinico Univertistario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Ignacio A Santos, Medicine &amp; Surgery</last_name>
      <phone>+34657923040</phone>
      <email>ijamat@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose R Delgado Arana, Medicine</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

